- Syncona will have a 23.0% stake in iOnctura
- Yellowstone is based in Oxford, UK
- Syncona will hold a 60.9% stake in Yellowstone
Syncona has made a €30 million investment in iOnctura and £16.5 million ($21 million; €19.5 million) in Yellowstone Biosciences.
Amsterdam-based iOnctura is a European clinical-stage biopharmaceutical company developing selective cancer therapeutics against targets that play critical roles in multiple tumour survival pathways.
